Nav: Home

US inroads to better Ebola vaccine

May 18, 2020

As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

The world cannot afford to take our eye of other threats, says Flinders University Professor Nikolai Petrovsky, who warns the highly lethal and infectious Ebola virus could appear in a more virulent form.

"While a live virus vaccine has recently been developed to protect against Ebola, it is not necessarily effective against all forms of Ebola and Marburg and is sensitive to heat which requires it to be stored frozen - a problem in poor tropical countries in Africa with erratic power supplies, which is where Ebola resides," he says.

In the latest collaboration with US partners, a vaccine turbocharger called Advax™ adjuvant, developed at Professor Petrovsky's Australian laboratory was combined with a synthetic protein against Ebola developed by the United States Army Medical Research Institute of Infectious Disease (USAMRIID).

The resulting vaccine appeared to be highly protective against a lethal Ebola virus infection in mice, including after just a single injection. As well, the protection generated by the vaccine was long-lasting and shown to be able to be transferred to naïve mice using antibodies taken from the immunised mice.

This work provides promise that a more convenient and heat stable version of the Ebola vaccine can be developed, which could then play a key role in preventing further Ebola outbreaks in Africa, Professor Petrovsky says.

"While developing a COVID-19 vaccine is a top priority including for our team, we must also continue developing vaccines against a wide range of other potentially catastrophic pandemic diseases including Ebola and Marburg viruses, as these continue to periodically jump from wild animals to people in Africa," he says.

The Petrovsky lab and Vaxine Pty Ltd is currently using the same Advax™ vaccine turbocharger approach to develop a recombinant protein vaccine against COVID-19, which is now in late stage animal testing ahead of human trials in Australia.

"Like coronaviruses, we must continue research into improving the world's vaccine pipeline for diseases, particularly rapidly changing viral infections believed to be transmitted to people from wild animals," he says.

The World Health Organisation notes Ebola virus disease (EVD) is a severe, generally fatal illness with an average case fatality of over 50%.

The 2014-2016 outbreak in West Africa was the largest and most complex Ebola outbreak with more cases and deaths than all others combined since the virus was discovered in 1976. It also spread between countries, starting in Guinea then moving across land borders to Sierra Leone and Liberia.

Infected patients travelled to many countries around the globe before the outbreak was stopped by quarantine measures.
-end-
The new publication, 'Adjuvant Selection Impacts the Correlates of Vaccine Protection against Ebola Infection' by Sabrina M. Stronsky, Christopher L. Cooper, Jesse Steffens, Sean Van Tongeren, Sina Bavari, Karen A. Martins (all US Army Medical Research Institute of Infectious Diseases) and Nikolai Petrovsky has been published in Vaccine (Elsevier) DOI: 10.1016/j.vaccine.2020.05.009 https://doi.org/10.1016/j.vaccine.2020.05.009

Flinders University

Related Ebola Articles:

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.
Ebola antibodies at work
Scientists in Israel and Germany show, on the molecular level, how an experimental vaccine offers long-term protection against the disease.
Half of Ebola outbreaks undetected
An estimated half of Ebola virus disease outbreaks have gone undetected since it was discovered in 1976, according to research published in PLOS Neglected Tropical Diseases.
Half of Ebola outbreaks go undetected, study finds
Half of Ebola outbreaks have gone undetected since the virus was discovered in 1976, scientists at the University of Cambridge estimate.
Protecting those on the frontline from Ebola
Online training developed at the Medical University of South Carolina (MUSC) increased the knowledge of health care workers about effective prevention of Ebola up to 19 percent and reduced critical errors to 2.3 percent in a small MUSC cohort.
Another piece of Ebola virus puzzle identified
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.
How the human immune system protects against Ebola
'The current approach for treatment of filovirus infections with antibody cocktails tested in animal models utilizes the principle of targeting of non-overlapping epitopes.
How to slow down Ebola
The phylogenetic tree of the 2013-2016 Ebola epidemic doesn't just tell us how the Ebola virus was able to evolve: it also reveals which events and preventive measures accelerated or slowed down its spread.
Study provides further insight into how Ebola affects the eye
A new study, conducted by the researchers from the University of Liverpool, published in JAMA Ophthalmology identifies the specific characteristics of Ebola retinal lesions, which provide further clues as to how the virus travels to the retina and causes damage.
New breakthrough paving the way for universal Ebola therapeutic
A new collaborative study has identified and studied Ebola antibodies that could be used to design universal therapeutics that are effective against many different Ebola species.
More Ebola News and Ebola Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Our Relationship With Water
We need water to live. But with rising seas and so many lacking clean water – water is in crisis and so are we. This hour, TED speakers explore ideas around restoring our relationship with water. Guests on the show include legal scholar Kelsey Leonard, artist LaToya Ruby Frazier, and community organizer Colette Pichon Battle.
Now Playing: Science for the People

#569 Facing Fear
What do you fear? I mean really fear? Well, ok, maybe right now that's tough. We're living in a new age and definition of fear. But what do we do about it? Eva Holland has faced her fears, including trauma and phobia. She lived to tell the tale and write a book: "Nerve: Adventures in the Science of Fear".
Now Playing: Radiolab

Uncounted
First things first: our very own Latif Nasser has an exciting new show on Netflix. He talks to Jad about the hidden forces of the world that connect us all. Then, with an eye on the upcoming election, we take a look back: at two pieces from More Perfect Season 3 about Constitutional amendments that determine who gets to vote. Former Radiolab producer Julia Longoria takes us to Washington, D.C. The capital is at the heart of our democracy, but it's not a state, and it wasn't until the 23rd Amendment that its people got the right to vote for president. But that still left DC without full representation in Congress; D.C. sends a "non-voting delegate" to the House. Julia profiles that delegate, Congresswoman Eleanor Holmes Norton, and her unique approach to fighting for power in a virtually powerless role. Second, Radiolab producer Sarah Qari looks at a current fight to lower the US voting age to 16 that harkens back to the fight for the 26th Amendment in the 1960s. Eighteen-year-olds at the time argued that if they were old enough to be drafted to fight in the War, they were old enough to have a voice in our democracy. But what about today, when even younger Americans are finding themselves at the center of national political debates? Does it mean we should lower the voting age even further? This episode was reported and produced by Julia Longoria and Sarah Qari. Check out Latif Nasser's new Netflix show Connected here. Support Radiolab today at Radiolab.org/donate.